Usefulness of suplatast tosilate in patients with mild bronchial asthma - Comparison with beclomethasone dipropionate

Allergology International

Volumn 54, Issue 1, 2005, Pages 131-135

  Horiguchi, Takahiko ^a   Kondo, Rieko ^a   Miyazaki, Junichi ^a   Shiga, Mamoru ^a   Hirose, Masahiro ^a   Ito, Tomohiro ^a   Fukumoto, Koji ^a   Torigoe, Hiroshi ^a   Tachikawa, Soichi ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Airway hypersensitivity; Anti allergic agents; Antiasthmatic drugs; Bronchial asthma; Inflammatory mediators

Indexed keywords

BECLOMETASONE DIPROPIONATE; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; SUPLATAST TOSYLATE;

ADULT; ALLERGIC REACTION; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; MALE; MILD INTERMITTENT ASTHMA; MILD PERSISTENT ASTHMA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH2 CELL;

EID: 17044362327     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.2332/allergolint.54.131     Document Type: Article

References (13)

1. Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N. Engl. J. Med. 1990;323:1033-1039.
2. Yanagihara Y, Kiniwa M, Ikizawa K, Shida T, Matsuura N, Koda A. Suppression of IgE production by suplatast tosilate-1151T (suplatast tosilate), a new dimethylsulfonium agent: 2 Regulation of human IgE response. Jpn. J. Pharmacol. 1993;61:31-39.
3. Yamaya H, Basaki Y, Togawa M, Kojima M, Kiniwa M, Matsuura N. Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents. Life Sci. 1995;56:1647-1654.
4. Tamaoki J, Kondo M, Sakai N et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomized study. Lancet 2000;356:273-278.
5. Horiguchi T, Tachikawa S, Handa M et al. Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness. J. Asthma 2001;38:331-336.
6. Immunity/Allergy Study Group in the Ministry of Health, Labor and Welfare. The guidelines for prevention and control of asthma in 2003. Tokyo:Kyowa Kikaku Tsushin, 2003;74: (in Japanese).
7. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-29.
8. Takashima T, Hida W, Sasaki H et al. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest 1981;80:600-606.
9. Foo Y Liew. Th1 and Th2 cells: a historical perspective. Nature Rev. Immunol. 2002;2:55-60.
10. Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nature Rev. Immunol. 2003;3:405-412.
11. Zhao GD, Yokoyama A, Kohno N, Sakai K, Hamada H, Hiwada K. Effect of suplatast tosilate (suplatast tosilate-1151 T) on a mouse model of asthma; inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int. Arch. Allergy Immunol. 2000;121:116-122.
12. Shim JJ, Dabbagh K, Takeyama K et al. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J. Allergy Clin. Immunol. 2000;105:739-745.
13. Sano Y, Miyamoto T, Makino S. Anti-inflammatory effect of suplatast tosilate on mild asthma. Chest 1997;112:862-863.